New products highlight ambiguity of orphan drug law.
Reid
Brian
B
D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D004465:Economic Competition; D000795:Fabry Disease / Q000188:drug therapy; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D007880:Legislation, Drug / Q000191:economics* / Q000592:standards; D008004:Licensure / Q000331:legislation & jurisprudence*; D009965:Orphan Drug Production / Q000191:economics / Q000331:legislation & jurisprudence* / Q000379:methods / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration; D000519:alpha-Galactosidase / Q000627:therapeutic use
D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta